Tempus AI Trades at Multi-Year Lows on AI Replacement Fears

Tempus AI continues to execute at a high level, according to a Seeking Alpha analysis. The stock trades at multi-year lows; the market fears generative AI will render the company's core asset–a proprietary dataset of clinical and genomic information–obsolete.

The fear centers on generative AI's ability to process medical data and deliver insights without Tempus's proprietary database. Large language models trained on public data, some argue, could offer cheaper precision medicine guidance, cutting out companies like Tempus that charge for access to their data.

The Seeking Alpha analysis counters that Tempus's data is not replicable by public web scraping. The company's dataset includes longitudinal clinical outcomes and molecular profiles from partnerships with hundreds of hospitals. That data is generated as part of routine clinical care, not through research projects. Each patient encounter adds structured and unstructured data to the system. Publicly available medical literature, by contrast, only captures published studies, which are a fraction of the total clinical picture. Tempus's dataset covers treatment decisions, outcomes, and follow-up in a way no public corpus does. Generative AI models lack access to that raw, structured information, the article argued.